Lek d. d.
Lek d.d., a prominent pharmaceutical company headquartered in Slovenia (SI), has been a key player in the industry since its establishment in 1946. With a strong presence in Central and Eastern Europe, Lek d.d. focuses on the development, production, and marketing of generic and innovative medicines, particularly in the fields of oncology, cardiovascular health, and central nervous system disorders. Renowned for its commitment to quality and innovation, Lek d.d. offers a diverse portfolio of products that cater to various therapeutic areas. The company has achieved significant milestones, including its integration into the Sandoz division of Novartis, enhancing its market position and global reach. Lek d.d. continues to be recognised for its contributions to healthcare, making it a trusted name in the pharmaceutical landscape.
DitchCarbon Score
How does Lek d. d.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Lek d. d.'s score of 40 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Lek d. d.'s reported carbon emissions
In 2023, Lek d.d. reported total carbon emissions of approximately 63,453 kg CO2e, comprising 42,900 kg CO2e from Scope 1, 19,070 kg CO2e from Scope 2, and 1,483 kg CO2e from Scope 3 emissions. This marks a significant reduction from previous years, with emissions in 2022 totalling about 92,722 kg CO2e, which included 59,500 kg CO2e from Scope 1, 26,120 kg CO2e from Scope 2, and 3,102 kg CO2e from Scope 3. The company has demonstrated a commitment to reducing its carbon footprint, although specific reduction targets or initiatives have not been disclosed. Lek d.d. has consistently reported emissions across all three scopes, indicating a comprehensive approach to tracking and managing its environmental impact. Overall, Lek d.d. is actively engaged in monitoring its carbon emissions, reflecting a growing awareness of climate responsibilities within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 5,549,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000 | 000,000 | 00,000 | 00,000 | 00,000 |
| Scope 2 | 29,613,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000 | 00,000 | 00,000 | 00,000 | 00,000 |
| Scope 3 | 30,239,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Lek d. d. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
